| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/01/2002 | US6335436 Antisense oligonucleotide coupled to ligand such as d-cycloserine, d-glucosamine, or biotin which binds to receptor on mycobacterium; hybridizes to aspartokinase or aspartate semialdehyde dehydrogenase genes |
| 01/01/2002 | US6335383 Microdispersions for coating surgical devices |
| 01/01/2002 | US6335365 Fireproof, non-exploding nitroglycerine and solid mixtures containing anhydrous lactose |
| 01/01/2002 | US6335356 Method of treating a patient by parenteral administration of a lipophilic compound |
| 01/01/2002 | US6335335 Prolonged-action eye drop |
| 01/01/2002 | US6335320 Method of treating fibrotic conditions |
| 01/01/2002 | US6335199 Gene therapy |
| 01/01/2002 | US6335163 Aggolomeration of receptor proteins; for use in diagnosis, treatment, and prevention of tumors, parasitic, bacterial and viral infections; for use in gene therapy |
| 01/01/2002 | US6335159 Retinoic acid receptor ε(rarε) |
| 01/01/2002 | US6335035 Hyaluronic acid salts blended with hydroxyethylcellulosea and hydroxypropylcellulose; analgesics |
| 01/01/2002 | US6335034 Topical drug preparations |
| 01/01/2002 | US6335033 Melt-extrusion multiparticulates |
| 01/01/2002 | US6335032 Orally administrable solid dosage form |
| 01/01/2002 | US6335031 (s)-n-ethyl-3-(1-dimethylamino)ethyl)-n-methyl-phenyl-carbamat salt form and antioxidant; alzheimer's disease therapy |
| 01/01/2002 | US6335030 Dextromethorphan, 3-methoxy-17-methyl-9a,13a,14a-morphanin, salts, prodrugs metabolites and carriers |
| 01/01/2002 | US6335029 Polymeric coatings for controlled delivery of active agents |
| 01/01/2002 | US6335028 Implantable particles for urinary incontinence |
| 01/01/2002 | US6335023 Vehicles and oligosaccharide aldonic acids |
| 01/01/2002 | US6335003 Fixing, controlling or shaping hair with diisocyanate, diol, primary or secondary amino alcohol, primary or secondary diamine or primary or secondary triamine with tertiary, quaternary or protonated tertiary amine nitrogen atoms |
| 01/01/2002 | CA2288677C Novel powder compositions |
| 01/01/2002 | CA2171939C Novel method of progesterone delivery and affect thereof |
| 01/01/2002 | CA2094267C Use of fatty alcohol based composition for preparing emulsions, method of preparing emulsions and emulsions so obtained |
| 01/01/2002 | CA2085490C Processes for the manufacture of enriched pitches and carbon fibers |
| 01/01/2002 | CA2081665C Oligosaccharide oxazolines, oligosaccharide conjugates and methods of preparation thereof |
| 01/01/2002 | CA2048544C Intravascular embolizing agent containing angiogenesis-inhibiting substance |
| 12/27/2001 | WO2001098522A2 Positively-charged peptide nucleic acid analogs with improved properties |
| 12/27/2001 | WO2001098364A2 Peptides, compositions and methods for the treatment of burkholderia cepacia |
| 12/27/2001 | WO2001098362A2 Chemically-modified antimicrobial peptides, compositions and methods of production and use |
| 12/27/2001 | WO2001098357A2 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 12/27/2001 | WO2001098329A1 Polyhydroxy glycopeptide derivatives |
| 12/27/2001 | WO2001098328A2 Glycopeptide phosphonate derivatives |
| 12/27/2001 | WO2001098327A2 Glycopeptide carboxy-saccharide derivatives |
| 12/27/2001 | WO2001098326A2 Glycopeptide disulfide and thioester derivatives |
| 12/27/2001 | WO2001098324A1 Peptide conjugates modified n- and/or c-terminally by short charged peptide chains |
| 12/27/2001 | WO2001098294A2 Vitronectin receptor antagonist pharmaceuticals for use in combination therapy |
| 12/27/2001 | WO2001098286A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 12/27/2001 | WO2001098235A2 3,4-dihydroxybenzyl-substituted carbonic acid derivatives and the use thereof as antioxidants |
| 12/27/2001 | WO2001097872A1 Bioadhesive compositions and methods of preparation and use |
| 12/27/2001 | WO2001097865A2 Multiple phase cross-linked compositions and uses thereof |
| 12/27/2001 | WO2001097862A2 Stabiliser for radiopharmaceuticals |
| 12/27/2001 | WO2001097859A1 Liposomal encapsulation of chelated actinium-225 and uses thereof |
| 12/27/2001 | WO2001097857A1 Preparations for oligonucleotide transfer |
| 12/27/2001 | WO2001097855A2 Targeted combination immunotherapy of cancer and infectious diseases |
| 12/27/2001 | WO2001097854A2 Method for the selective survival or selective growth of a target cell by the use of a conjugate, its use in therapeutics and/or diagnostics |
| 12/27/2001 | WO2001097853A1 Improvement of itraconazole bioavailability |
| 12/27/2001 | WO2001097851A2 Compositions and methods to improve the oral absorption of antimicrobial agents |
| 12/27/2001 | WO2001097848A2 Vitronectin receptor antagonist pharmaceuticals |
| 12/27/2001 | WO2001097844A1 Bispecific fusion protein and method of use for enhancing effector cell killing of target cells |
| 12/27/2001 | WO2001097837A1 Solubilised protein vaccines |
| 12/27/2001 | WO2001097834A1 Matrix protein compositions for dentin regeneration |
| 12/27/2001 | WO2001097832A1 Pharmaceutical preparations containing cyclosporines and neutral oils |
| 12/27/2001 | WO2001097813A2 Highly concentrated stable meloxicam solutions |
| 12/27/2001 | WO2001097803A1 Pharmaceutical preparations comprising racecadotril (acetorphan) |
| 12/27/2001 | WO2001097800A1 Method of stabilizing medicinal compositions containing pravastatin |
| 12/27/2001 | WO2001097796A1 Clear aqueous anaesthetic composition |
| 12/27/2001 | WO2001097795A2 Systems and methods for treating a mucosal surface |
| 12/27/2001 | WO2001097783A1 Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms |
| 12/27/2001 | WO2001097782A1 Stable gabapentin having ph within a controlled range |
| 12/27/2001 | WO2001097781A1 Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake |
| 12/27/2001 | WO2001097779A2 Improved injectable dispersions of propofol |
| 12/27/2001 | WO2001097778A2 Amphotericin b structured emulsion |
| 12/27/2001 | WO2001097777A1 Topical preparation of alprostadil for the treatment of erectile dysfunction |
| 12/27/2001 | WO2001097774A2 Novel pharmaceutical composition for the topical application of water-insoluble and/or hardly water-soluble active agents |
| 12/27/2001 | WO2001097749A2 The use of synthetic, non-hormonal 21-aminosteroids and thereof |
| 12/27/2001 | WO2001097678A2 Imaging and targeting tumors using sickle cells |
| 12/27/2001 | WO2001097611A1 Positively charged poly[alpha-(omega-aminoalkyl)glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake |
| 12/27/2001 | WO2001064605A3 Generation and screening of a dynamic combinatorial library |
| 12/27/2001 | WO2001062086A8 Nutritional intervention composition for enhancing and extending satiety |
| 12/27/2001 | WO2001051024A3 Implantation kit comprising a support phase and a solvent |
| 12/27/2001 | WO2001047549A3 Conjugate useful as building block for vaccine preparation |
| 12/27/2001 | WO2001047372A3 Absorbing fat chitosan |
| 12/27/2001 | WO2001037782A3 Method and composition for the treatment of scars |
| 12/27/2001 | WO2001030336A3 Pharmaceutical formulations comprising resveratrol and use thereof |
| 12/27/2001 | WO2001026693A3 Manufacture of polyglutamate-therapeutic agent conjugates |
| 12/27/2001 | WO2001021159A3 Pharmaceutical composition of nateglinide and another antidiabetcagent |
| 12/27/2001 | WO2000064485A3 Specifically targeted catalytic antagonists and uses thereof |
| 12/27/2001 | US20010056301 Hydrogel biomedical articles |
| 12/27/2001 | US20010056205 3-Methoxybenzyl thiourea derivatives and improved lipid compositions containing same |
| 12/27/2001 | US20010056183 Sulfonamides and derivatives thereof that modulate the activity of endothelin |
| 12/27/2001 | US20010056171 By reacting a di(1-benzotriazolyl)carbonate with a hydroxyl-terminated non-peptidyl polymer such as polyether; conjugating proteins, amino acids such as lysine, peptides, drugs, nucleosides to the modified polymer |
| 12/27/2001 | US20010056127 Contains molecular iodine in a concentration above at least 15 ppm and one of triiodide or complexed iodoine may be present; lower concentrations of iodine disinfect without staining skin |
| 12/27/2001 | US20010056116 A prodrug compound capable of facilitating the passage of a drug across the blood brain barrier comprising a fatty acid coupled to a drug to form a prodrug |
| 12/27/2001 | US20010056098 Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid |
| 12/27/2001 | US20010056093 Olopatadine and emedastine and an ophthalmically acceptable polymeric quaternary ammonium compound as a preservative |
| 12/27/2001 | US20010056070 Introducing intratumoral dose of paclitaxel formulation and subsequently providing initial intravenous infusion of paclitaxel about 24 hours to about 7 days after the intratumoral dose; antitumor agents |
| 12/27/2001 | US20010056062 As osmotic agents synthetic polypeptides of two to fifteen amino acids long; slow transport across the peritoneum, for prolonged osmotic gradient between dialysate and blood |
| 12/27/2001 | US20010055807 Immunoisolation of a cell; least one cell is encapsulated with a coating having a polyelectrolyte charge opposite to the charge of the cell/poly-beta-N-acetylglucosamine species |
| 12/27/2001 | US20010055751 PSCA: Prostate stem cell antigen and uses thereof |
| 12/27/2001 | US20010055622 Antimicrobial bioabsorbable materials |
| 12/27/2001 | US20010055620 Compaction; particle coatings |
| 12/27/2001 | US20010055619 Mixture of polymethacrylate and carboxymethyl cellulose |
| 12/27/2001 | US20010055617 Method and preparations for stabilizing biological materials by drying methods without freezing |
| 12/27/2001 | US20010055616 Multilayer; active material core, enteric coating |
| 12/27/2001 | US20010055614 Osmosis dosage form |
| 12/27/2001 | US20010055613 Oral pulsed dose drug delivery system |
| 12/27/2001 | US20010055611 Freeze drying |
| 12/27/2001 | US20010055595 Detection and treatment of infections with immunoconjugates |
| 12/27/2001 | US20010055586 Methods and means for targeted gene delivery |
| 12/27/2001 | US20010055583 Methods of preventing aggregation of various substances upon rehydration or thawing and compositions obtained thereby |
| 12/27/2001 | US20010055582 Erythropoietin solution preparation |